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Introduction: Aspirin (ASA) and clopidogrel are still primary treatment options for
patients with acute coronary syndrome (ACS). The application of dual antiplatelet
therapy (DAPT) is also known to reduce major cardiovascular events for such patients.
However, DAPT has been shown to have serious gastrointestinal (GI) side effects and
to avoid these side effects the proton pump inhibitors (PPI) are added to the treatments
for many patients. There are conﬂicting reports in the literature whether the use of
PPI with clopidogrel increases major cardiovascular events or not. In this study, we
planned to investigate the effects of the use of PPI, in addition to DAPT, towards
developing major cardivascular events on the patients treated in the intensive care unit,
and whether these effects differ among PPIs.
Methods: 303 patients with ACS from the intensive care unit were included in this
study. While all of the patients were using ASA and clopidogrel, 232 of them were
using PPI. The patients using PPI were divided into 4 groups according to the types of
PPI which are lansoprazole, pantoprazole, omeprazole and rabeprazole. In-hospital
angina pectoris, shortness of breath, changes in ECG, cardiac enzyme elevation, heart
failure, arrhythmias, and reinfarct development, coronary angiography (CAG) and
percutaneous coronary intervention (PCI) requirement, the development of GI
bleeding and mortality were examined on these patients. The same data was evaluated
at ﬁrst and sixth months after discharge.
Findings: In our study no difference was observed between PPI users and non-users
in terms of in-hospital angina pectoris, dyspnea, arrhythmia, the development of heart
failure and ACS, need for CAG or PCI, development of GI bleeding and mortality.
When the PPI groups were evaluated among each other, the development of dyspnea
and heart failure was seen more in the patients using omeprazole. However, it was
realized that either these patients had initially been accepted with the shortness of
breath and heart failure complaints, or they had needed an intra-aortic balloon pump
and had been treated with omeprazole as the only intravenous PPI option available to
us at the time. At the end of the ﬁrst and sixth months there were no differences found
in terms of the development of cardiovascular events.
Conclusion: It is concluded that the PPI use does not have any negative impacts of
causing development of cardiovascular events in intensive care unit patients who are
diagnosed with acute coronary syndrome and who are receiving DAPT. Moreover, it
is seen that the combination of clopidogrel and PPI treatments are safe. In addition, no
differences were observed among the subgroups of PPI.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAInterventional Cardiology
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Aim: Contrast induced nephropathy is associated with permanent renal dysfunction
and increased mortality. Few data is available regarding its effect on event-free
survival of patients with non-ST elevation myocardial infarction (NSTEMI).
Methods: Patients with NSTEMI who underwent early coronary angiography were
analysed retrospectively. Exclusion criteria were previous exposure to contrast agents
within 7 days, hemodynamic instability or emergent procedures, and end stage renal
failure requiring chronic hemodialysis treatment. Contrast induced nephropathy (CIN)
was deﬁned as either 25% or 0.5 mg/dl increase in preprocedural serum creatinine
within 72 hours of the procedure. Follow-up data of patients were acquired from
hospital records. Patients without follow-up data were invited to hospital by phone
call. Clinical endpoints of the study were mortality and nonfatal myocardial infarction
(MI) in long term follow-up.
Results: 312 consecutive patients (mean age 5912 years, 76% male) with complete
serum creatinine measurements and long term clinical follow-up data (median
38 months) were included in the study. CIN developed in 9.6% (30) of patients.
Independent predictors of CIN were contrast volume/estimated glomerular ﬁltration
rate ratio [odds ratio 1.294 (1.062-1.577), p¼.011], left ventricular ejection fraction
[odds ratio 0.950 (0.911-0.990), p¼0.015] and hemoglobin concentration [odds ratio
0.755 (0.601-0.949), p¼0.016]. Death or nonfatal myocardial infarction was observed
more frequently in patients with CIN during the follow-up compared to patients
without (43.3% vs 19.9% respectively, chi-square¼10.4, log rank p¼0.005). Inde-
pendent predictors of long term mortality were left ventricular ejection fraction
[X2¼23,5, OR¼0.930 (0.903-0.958), p<0.001], age [X2¼4.3, OR¼1.028 (1.002-
1.056), p<0.038], and baseline creatinine [X2¼4.2, OR¼1.725 (1.021-2.913),
p¼0.042].
Conclusion: CIN after invasive procedures in patients with NSTEMI is associated
with increased mortality and cardiac events. Patients who developed CIN during acute
coronary syndromes should be considered as high-risk group and clinical follow-up
should be done accordingly. However CIN is not an independendent predictor of long
term mortality or recurrent events in patients with NSTEMI.LS C57
Heart rate increase during dobutamine infusion
Control
Mean HR,
bpm
Beta Blocker
Mean HR,
bpm
Ivabradine
Mean HR,
bpm p
Baseline 81.911.7 75.613.4 82.117.3 0.324
DOB 5 mg/kg/min 90.316.6* 82.313.9z 82.415.7 0.118
DOB 10 mg/kg/min 97.714.8y# 86.114.1y 85.114.9 0.003
DOB 15 mg/kg/min 101.716.9yx 88.713.5ya 83.512.4 0.001
P (Two-way ANOVA) 0.001 0.001 0.439
*p¼0.001, zp¼0.009 and yp¼0.0001 compared with baseline. ap¼0.013, #p¼0.006 and
xp¼0.0001 compared with DOB 5 mg/kg/min.
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Toxic Chemical Elements in Hair Composition of Patients with Myocardial
Infarction
Tatyana Mikolayivna Solomenchyk
Lviv National Medical University n.a. Danylo Halytsky, Ukraine
Purpose: Hair elemental composition assessment in patients with myocardial
infarction (MI) aged under 50 years to establish basic essential and toxic chemical
elements balance and evaluation of the degree of “contamination” with xenobiotics.
Methods: X-ray ﬂuorescence spectrometry multielement assay of hair composition
was performed in 23 healthy persons and 39 patients with MI in 2 groups. 1st group
included 28 patients whose occupation is related to action of xenobiotics (drivers,
turners, seamstresses, welders, house-painters), 2nd group – 11 patients who had no
occupational contact with xenobiotics (engineers, managers, teachers, accountants,
housewives, etc.). Hair concentration of 28 elements was studied.
Results: The highest degree of “contamination” with xenobiotics was found
among patients that had continuous contact with chemical substances. Reliably higher
levels of heavy metals (iron, copper, manganese, chromium, cadmium, lead), high-
activity toxic low density metals (strontium, rubidium), sulfur, potassium, bromine and
chlorine were revealed in their hair in comparison with control and 2nd group. Bromine
nowadays is used as antiknock agent admixture to gasoline taking into account that
majority of the 1st group is represented by drivers. Mean concentrations of potassium
and strontium 1,5-1,9 times exceeded maximum permissible doses.
Patients with MI without harmful occupational factors showed relatively higher
levels of chlorine (2,3 times), lead (1,6 times) and quicksilver than control that
may indicate penetration of xenobiotic from feasibly environmental impact and
smoking.
Regardless of occupation, patients with myocardial infarction under 50 years old
have high incidence of decreased level of protective element – selenium.
Conclusion: Reliably higher levels of certain essential and toxic elements in patients
with myocardial infarction than in healthy subjects may be scrutinized as the evidence
of direct cause-effect relation between xenobiotic's impact and development of
coronary disease in subjects under 50, especially in case of absent or low grade
traditional cardiovascular risk factors.1
Toxic chemical
elements
(mcgr/gr)
Control
(n¼23)
1st group
(n¼28)
2nd group
(n¼11) permissible doses
Chlorine (Cl) 68,0  50,13 * 207,05  118,34 155,87  87,86 * 60,0 - 560,0
Strontium (Sr) 2,51  1,16 * 9,66  7,26 ** 3,52  2,67 0,5 - 5,0
Lead (Pb) 0,57  0,20 * 1,65  0,90 ** 0,89  0,47 0,1 - 5,0
Zirconium (Zr) 0,27  0,19 * 0,48  0,44 0,33  0,23 0 - 1,5
Rubidium (Rb) 0,21  0,19 * 0,36  0,27 ** 0,18  0,10 0,05 - 1,5
Mercury (Hg) 0 * 0,25  0,18 0,39  0,35 0,05 - 0,2
Arsenic (As) 0,09  0,15 0,21  0,23 0,17  0,21 0,005 - 0,1
Cadmium (Cd) 0,06  0,04 * 0,09  0,06 0,07  0,05 0,05 - 0,25
* - reliability of difference compared with control, ** - between groups
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Ivabradine Treatment Blunts Dobutamine-Induced Increase in Heart Rate in
Patients with Acute Decompensated Heart Failure: A Comparative Study with
Beta-Blocker Therapy
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Bektas Morrad, Taner Ulus
Eskisehir Osmangazi University, Eskisehir
Purpose: Ivabradine is a selective If channel inhibitor that results in heart rate (HR)
reduction without affecting contractility. Beta-adrenergic stimulation increases intra-
cellular cAMP that positively shifts the If channel activation curve, increases the slope
of the diastolic depolarization and accelerates HR. Dobutamine (DOB) is well-known
to increase HR and energy expenditure, and thereby may precipitate ischemia and
myocyte damage. The aim of this study was to evaluate whether ivabradine treatment
blunts DOB-induced increase in HR.
Methods: Seventy three acute decompensated heart failure (HF) patients requiring
inotropic support, LVEF <35% and in sinus rhythm were included in the study. All
patients underwent holter recording for 6-h before the initiation of DOB and then DOB
was administered at incremental doses of 5, 10 and 15 mgr/kg/min, with 6-h steps. Holter
monitoring was continued during 18 h of DOB infusion. Ivabradine 7.5 mg was given at
the time of the initiation of DOB and readministered at 12 h of DOB infusion in 29
patients not receiving beta-blocker (Ivabradine group). 15 patients who were on beta-
blocker therapy (beta-blocker group) and 29 patients not taking beta-blocker therapy
(control group) did not receive ivabradine during DOB infusion. Holter recordings were
analyzed for mean HR change for each step of study protocol.
Results: Baseline mean HR was similar among three groups. In both control and
beta-blocker groups,meanHRgradually and signiﬁcantly increased at each step ofDOB
infusion (table). However, in ivabradine group, no signiﬁcant change was observed in
mean HR with incremental doses of DOB infusion. Mean HR during the two highest
doses of DOB infusionwas found to be signiﬁcantly higher in control group among three
groups. Two-way ANOVA analysis also suggested a signiﬁcant rise in mean HR in
control group (p<0.001), a slight but signiﬁcant increase in beta-blocker group (p
<0.001) and no signiﬁcant increase in HR in ivabradine group (p¼0.439).
Conclusions: This study showed that ivabradine treatment blunts DOB-induced
increase in HR in patients with acute decompensated HF and may be useful in
reducing heart rate-related adverse effects of DOB.General
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Irbesartan Ameliorates Myocardial Ischaemia/Reperfusion Injury in Rats Via
Down Regulation of Apoptosis and the Inﬂammatory Pathways
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Background: Myocardial ischemia–reperfusion represents a clinically relevant
problem associated with thrombolysis, angioplasty and coronary bypass surgery.
Injury of myocardium due to ischemia–reperfusion includes cardiac contractile
dysfunction, arrhythmias as well as irreversible myocytes damage. These changes are
considered to be the consequence of imbalance between the formation of oxidants and
the availability of endogenous antioxidants in the heart.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
